ライフサイエンスコーパス: haemorrhagic

1 80% of strokes are ischaemic, as opposed to haemorrhagic.

2 Although traumatic and haemorrhagic acute brain injury are generally considered

3 MRI detected acute stroke (ischaemic or haemorrhagic), acute ischaemic stroke, and chronic haemo

4 er alone or in combination: grade 3 or worse haemorrhagic adverse events; platelet counts of less tha

5 tion of these venom components to the severe haemorrhagic and coagulopathic pathology of envenoming a

6 of interests were 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial i

7 ic, half of incident strokes in children are haemorrhagic and half are ischaemic.

8 y emphasise the counter-balancing effects of haemorrhagic and ischaemic complications after stent imp

9 ripheral vessel AVMs, stroke (separately for haemorrhagic and ischaemic), transient ischaemic attack

10 setts General Hospital (Boston, MA, USA) for haemorrhagic and non-haemorrhagic CAA markers, and brain

11 In post-haemorrhagic and other forms of communicating hydrocepha

12 ion levels provides prevalent treatments for haemorrhagic and thromboembolic diseases(5).

13 ere the first diagnosis of thrombocytopenic, haemorrhagic and thromboembolic events in primary or sec

14 r, the actual risk stratification models for haemorrhagic and thrombotic events are not validated in

15 total cholesterol was negatively related to haemorrhagic and total stroke mortality.

16 and multifocal brain injuries of ischaemic, haemorrhagic and traumatic aetiology.

17 zations occur spontaneously after ischaemic, haemorrhagic and traumatic brain injury.

18 ated with cSVD-related stroke (ischaemic and haemorrhagic) and MRI-defined covert cSVD.

19 fatal stroke, and death from cardiovascular, haemorrhagic, and unknown causes (Antiplatelet Trialists

20 e and small infarcts, many of which appeared haemorrhagic; and microglial activation with microglial

21 ions, increased NCAM expression and produced haemorrhagic angiogenesis in mouse matrigel implants.

22 ith OCCC-like histopathology, culminating in haemorrhagic ascites and a median survival period of 7.5

23 verity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale)

24 erebrovascular physiology, (stage three) non-haemorrhagic brain injury, and (stage four) appearance o

25 Haemorrhagic brain lesions were found in 9/31 (29%) case

26 brain injury, and (stage four) appearance of haemorrhagic brain lesions.

27 l (Boston, MA, USA) for haemorrhagic and non-haemorrhagic CAA markers, and brain tissue samples were

28 cardiac arrest (n=1 in apixaban group), and haemorrhagic cerebral sinus vein thrombosis (n=1 in the

29 n in central blood volume during a simulated haemorrhagic challenge combined with heat stress.

30 in regional blood volumes during a simulated haemorrhagic challenge imposed via lower-body negative p

31 ons in the capacity to withstand a simulated haemorrhagic challenge; however, this capacity is normal

32 minated encephalomyelitis, particularly with haemorrhagic change, is striking.

33 Any associated oedema or haemorrhagic changes may alter the prognosis and have to

34 Viper venom induced haemorrhagic, coagulant and anticoagulant activities wer

35 Escherichia coli O157:H7 causes diarrhoea, haemorrhagic colitis, and the haemolytic uraemic syndrom

36 asymptomatic shedding, non-bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome, and d

37 EC) serotype O157:H7, the causative agent of haemorrhagic colitis, has been shown to utilize a cell-t

38 and has been implicated in many outbreaks of haemorrhagic colitis, some of which included fatalities

39 y practiced by recognizing the presence of a haemorrhagic collection and how it predominates in deter

40 erapeutic for the treatment of juvenile post-haemorrhagic communicating hydrocephalus.

41 ed data on predictors of early ischaemic and haemorrhagic complications after AF-associated ischaemic

42 ad substantially lower 30-day rates of major haemorrhagic complications and net adverse clinical even

43 Predictors of long-term ischaemic and haemorrhagic complications in atrial fibrillation (AF) h

44 also associated with early recanalisation or haemorrhagic complications, and early neurologic deterio

45 ile significantly lowering the risk of major haemorrhagic complications.

46 DMVO, it is associated with higher risks of haemorrhagic complications.

47 ent outcome (mRS 0-1), mortality (mRS 6) and haemorrhagic complications.

48 Acute haemorrhagic conjunctivitis (AHC) outbreaks are reported

49 man who had an ischaemic stroke with massive haemorrhagic conversion requiring a decompressive hemicr

50 ogenic oedema, and catastrophic failure with haemorrhagic conversion.

51 sfunction, resulting in oedema formation and haemorrhagic conversion.

52 topenia (BNP; previously known as idiopathic haemorrhagic diathesis and commonly known as bleeding ca

53 Elephant endotheliotropic herpesvirus haemorrhagic disease (EEHV-HD) is widely acknowledged as

54 Rabbit Haemorrhagic Disease (RHD) causes high morbidity and mor

55 ation when applied to specific cases--rabbit haemorrhagic disease and fox rabies.

56 apoptosis.Importance Responsible for severe haemorrhagic disease in domestic pigs and wild boar, cla

57 an swine fever virus (ASFV) causes a lethal, haemorrhagic disease in domestic swine that threatens pi

58 nce that causes severe leukopenia, fever and haemorrhagic disease in domesticated pigs and wild boar

59 ly identified viruses associated with severe haemorrhagic disease in humans in China and the US.

60 EEHV-induced haemorrhagic disease is a major threat to juvenile Asian

61 known as bleeding calf syndrome) is a novel haemorrhagic disease of young calves which has emerged i

62 Recently, a new variant of the rabbit haemorrhagic disease virus (RHDV2 or RHDVb) arguably cau

63 Haemorrhagic disease, encephalitis, biphasic fever, flac

64 r research on the pathogenesis of nairoviral haemorrhagic disease.

65 Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dy

66 trolling excessive bleeding in patients with haemorrhagic disorders.

67 ding anaemia, malignant blood disorders, and haemorrhagic disorders.

68 had recurrent strokes (12 ischaemic and two haemorrhagic) during a median follow-up of 2.8 years (IQ

69 io 0.51; 95% CI 0.31-0.85) but not for major haemorrhagic events (0.88, 0.74-1.06) or death (0.82, 0.

70 vein thrombosis, or pulmonary embolism) and haemorrhagic events (symptomatic intracranial or signifi

71 ation had a high risk of both thrombotic and haemorrhagic events after stroke.

72 r risk of thrombotic events or lower risk of haemorrhagic events benefited from heparins.

73 (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Syste

74 -PCI infusion or heparin (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Syste

75 led in the MATRIX-Access (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Syste

76 sub-study of the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Syste

77 (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Syste

78 c events was 0.63 (95% CI 0.59-0.67) and for haemorrhagic events was 0.60 (0.55-0.64).

79 uartiles of predicted risk of thrombotic and haemorrhagic events with random effect meta-analysis.

80 of venous thrombotic events or a low risk of haemorrhagic events.

81 k of thrombotic events or decreasing risk of haemorrhagic events.

82 by 580 ischaemic stroke patients with 12.1% haemorrhagic events.

83 recurrent clinically diagnosed ischaemic or haemorrhagic (excluding subarachnoid haemorrhage) stroke

84 Crimean-Congo haemorrhagic fever (CCHF) is a severe febrile illness tr

85 Crimean-Congo haemorrhagic fever (CCHF) is a severe tick-borne illness

86 ultiorgan dysfunction in COVID-19 and dengue haemorrhagic fever (DHF) are two diseases that can assoc

87 Some infections result in dengue haemorrhagic fever (DHF), a syndrome that in its most se

88 life-threatening form of the disease, dengue haemorrhagic fever (DHF).

89 equently and results in Lassa fever, a viral haemorrhagic fever (VHF) associated with a high case fat

90 Importantly, one case of Crimean-Congo haemorrhagic fever and two cases each of Rift Valley fev

91 describing the coagulopathy of Crimean-Congo haemorrhagic fever are scarce.

92 at TfR1 is a cellular receptor for New World haemorrhagic fever arenaviruses.

93 Lassa fever is an haemorrhagic fever caused by Lassa virus (LASV).

94 Outbreaks of haemorrhagic fever caused by the Ebola virus are associa

95 Lassa fever is a viral haemorrhagic fever endemic in parts of west Africa.

96 Lassa fever (LF) is a viral haemorrhagic fever endemic in West Africa and spread pri

97 underlying the potential of widespread viral haemorrhagic fever epidemics.

98 nd Marburg filoviruses cause a rapidly fatal haemorrhagic fever in humans for which no approved antiv

99 g Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans.

100 e causative agents of a severe form of viral haemorrhagic fever in man, designated Ebola haemorrhagic

101 us, was associated with an outbreak of acute haemorrhagic fever in Mangala, Democratic Republic of th

102 mic Large DNA Virus that causes an incurable haemorrhagic fever in pigs with a high impact on global

103 o hospitals with PCR-confirmed Crimean-Congo haemorrhagic fever in Samsun and Tokat, Turkey.

104 Furthermore, Ebola haemorrhagic fever is currently spreading through ape po

105 Coagulopathy of Crimean-Congo haemorrhagic fever is related to defects in clot develop

106 Ebola virus outbreaks causing viral haemorrhagic fever occur predominantly in regions with h

107 indow into the evolution of an ongoing viral haemorrhagic fever outbreak.

108 vary within Africa, with regions where viral haemorrhagic fever outbreaks have previously occurred (e

109 gests that the coagulopathy of Crimean-Congo haemorrhagic fever relates to platelet dysfunction.

110 We used a rhesus macaque model of MARV haemorrhagic fever that produced 100% lethality.

111 ation testing in patients with Crimean-Congo haemorrhagic fever to increase our understanding of the

112 Virus detection using MSSPE arboviral or haemorrhagic fever viral panels was comparable in sensit

113 prophylaxis or vaccine against Crimean-Congo haemorrhagic fever virus (CCHFV).

114 ruses to humans, including the Crimean-Congo haemorrhagic fever virus (CCHFV).

115 resembling that observed with Crimean-Congo Haemorrhagic Fever virus in humans.

116 ses like Rift Valley fever and Crimean-Congo haemorrhagic fever viruses continue to emerge in new geo

117 arito, Junin and Sabia viruses are New World haemorrhagic fever viruses that do not use alpha-dystrog

118 of tick-borne encephalitis and Crimean-Congo haemorrhagic fever viruses, have changed their geographi

119 15, 65 patients with confirmed Crimean-Congo haemorrhagic fever were recruited and had blood taken at

120 ied by muroid rodents and cause the diseases haemorrhagic fever with renal syndrome (HFRS) and hantav

121 egative association between the incidence of haemorrhagic fever with renal syndrome and the species r

122 ecies richness and incidence of rodent-borne haemorrhagic fever with renal syndrome in the human popu

123 ilovirus that causes severe and often lethal haemorrhagic fever(1,2).

124 us, idiopathic pulmonary fibrosis and dengue haemorrhagic fever).

125 haemorrhagic fever in man, designated Ebola haemorrhagic fever, and are endemic in regions of centra

126 haemorrhagic fevers in Africa, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, an

127 We used a rhesus macaque model of Ebola haemorrhagic fever, which produces near 100% mortality.

128 usly efficient vectors of malaria and Dengue haemorrhagic fever.

129 arburg filoviruses cause deadly outbreaks of haemorrhagic fever.

130 s a model for the treatment of ZEBOV-induced haemorrhagic fever.

131 rmly lethal non-human primate model of ZEBOV haemorrhagic fever.

132 ephalitis, Kyasanur Forest disease, and Omsk haemorrhagic fever.

133 rovides a paradigm for the treatment of MARV haemorrhagic fever.

134 loped clinical symptoms consistent with MARV haemorrhagic fever.

135 respiratory syndrome), avian influenza, and haemorrhagic fever.

136 (rVSV), as a postexposure treatment for MARV haemorrhagic fever.

137 athway could ameliorate the effects of Ebola haemorrhagic fever.

138 pact on temporal dynamics of cases of dengue haemorrhagic fever.

139 s: filamentous, enveloped viruses that cause haemorrhagic fever.

140 gue, and 85.9% (31.9 to 97.1) against dengue haemorrhagic fever.

141 ging pathogens and causative agents of viral haemorrhagic fever.

142 ubnational pandemic potential for four viral haemorrhagic fevers in Africa, Crimean-Congo haemorrhagi

143 At least five arenaviruses cause viral haemorrhagic fevers in humans.

144 Of the multiple arenaviruses that cause haemorrhagic fevers in the Americas, all lack reliable t

145 apies for emerging diseases, including viral haemorrhagic fevers such as those caused by Ebola virus

146 onse syndromes in bacterial sepsis and viral haemorrhagic fevers, and anticoagulants can be effective

147 lance and response capacity to contain viral haemorrhagic fevers.

148 the onset of symptoms, among whom 1029 had a haemorrhagic form of stroke.

149 was associated with several inflammatory and haemorrhagic gastrointestinal diseases, including oesoph

150 icant differences were found between the non-haemorrhagic group and the haemorrhagic group regarding

151 d between the non-haemorrhagic group and the haemorrhagic group regarding the number of outflows (p =

152 h approximately 15% of strokes in adults are haemorrhagic, half of incident strokes in children are h

153 6.3%) in children, and tumours (24.6%), post-haemorrhagic hydrocephalus (16.2%) and idiopathic normal

154 stream regulator of Yap that can cause fetal haemorrhagic hydrocephalus, deregulates Yap in the devel

155 ral CB1 cannabinoid receptors contributes to haemorrhagic hypotension, and anandamide produced by mac

156 Lassa virus (LASV) can cause Lassa fever, a haemorrhagic illness with an estimated fatality rate of

157 and cortical superficial siderosis-a new CAA haemorrhagic imaging signature and (b) whether acute cSA

158 plications (one cerebral haemorrhage and one haemorrhagic infarct) directly related to surgery.

159 in 88 (29.3%) patients, among which 62 were haemorrhagic infarction and 26 were parenchymal haemorrh

160 atrix, small-to-large IVH or periventricular haemorrhagic infarction.

161 Given that a haemorrhagic injury on the battlefield is almost always

162 al haemorrhage occur after the initial acute haemorrhagic insult subsides, and represent one of its m

163 that are beneficial in defending against the haemorrhagic insult.

164 does not compromise tolerance to a simulated haemorrhagic insult.

165 was fatal or disabling stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or clinically s

166 the periods post-first dose of BNT162b2 for haemorrhagic (IRR 1.47, 95%CI: 1.04-2.08) and idiopathic

167 S-CoV-2 infection the risk was increased for haemorrhagic (IRR 1.49, 95%CI: 1.15-1.92), VTE (IRR 5.63

168 (ARIA-E) in brain parenchyma or sulci or as haemorrhagic lesions (ARIA-H) in the form of cerebral mi

169 early embryonic deaths, abortions, and necro-haemorrhagic lesions had observed.

170 hat cerebral amyloid angiopathy (CAA) causes haemorrhagic lesions in cerebellar cortex as well as sub

171 omatic intracranial haemorrhage or surrogate haemorrhagic lesions on MRI scans, whereas later DOAC-ad

172 y with prolonged bleeding and progression of haemorrhagic lesions, the risk of hypercoagulopathy with

173 rosis and other white-matter diseases (acute haemorrhagic leucoencephalitis, leucodystrophies and cen

174 cular death (both overall and in subgroups), haemorrhagic major adverse cardiovascular events, and fu

175 investigated associations with ischaemic and haemorrhagic manifestations of small vessel disease [sma

176 tro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, and leukopenia; fever and a

177 a severe multisystem disease that often has haemorrhagic manifestations.

178 Haemorrhagic markers progressed during follow-up.

179 Immediate haemorrhagic mortality constitutes the largest group of

180 bsequent collapse of tumours, similar to non-haemorrhagic necrosis in ischaemia and unlike haemorrhag

181 aemorrhagic necrosis in ischaemia and unlike haemorrhagic necrosis induced by tumour necrosis factor.

182 e mice die from hepatocellular apoptosis and haemorrhagic necrosis.

183 Since type C isolates cause both haemorrhagic necrotic enteritis and fatal enterotoxemias

184 getative cultures of wild-type CN3685 caused haemorrhagic necrotizing enteritis in rabbit ileal loops

185 2 QS system, is required for CN3685 to cause haemorrhagic necrotizing enteritis, apparently because t

186 ical superficial siderosis is an established haemorrhagic neuroimaging marker of cerebral amyloid ang

187 e study areas and not associated with deadly haemorrhagic or debilitating syndromes.

188 duals experienced either a thrombocytopenic, haemorrhagic or thromboembolic event during the study pe

189 images results in the detection of more 'non-haemorrhagic' pathology.

190 Ischaemic or haemorrhagic perioperative stroke (that is, stroke occur

191 Haemorrhagic presentation peaked between ages 7 and 14,

192 incidence of childhood stroke (ischaemic and haemorrhagic) range from 2.3 to 13.0 per 100,000 childre

193 The classic features of haemorrhagic rash, meningism, and impaired consciousness

194 ons for fatal rather than non-fatal, and for haemorrhagic rather than ischaemic stroke.

195 rct growth, enhance reperfusion, or decrease haemorrhagic risk has gained renewed interest with the h

196 Given the low haemorrhagic risk of intracranial low-grade dural arteri

197 The haemorrhagic risks of the combination of aspirin and clo

198 c differences in the baseline thrombotic and haemorrhagic risks.

199 f, but was abundant in the choroid plexus of haemorrhagic samples.

200 t late seizure following an immediately post-haemorrhagic seizure; and (ii) investigate the effect of

201 Haemorrhagic septicaemia (HS) is an economically importa

202 s suggest a bacterial septicaemia similar to haemorrhagic septicaemia caused by P. multocida.

203 Adults (age >=16 years) with trauma-related haemorrhagic shock and hypotension (defined as systolic

204 olar epithelium in the early phase following haemorrhagic shock by attenuating NO-mediated oxidative

205 ort across the alveolar epithelium following haemorrhagic shock is mediated by reactive nitrogen spec

206 We treated a 2.9 kg neonate with haemorrhagic shock, multiple organ dysfunction, and seve

207 rease in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normote

208 n (TICI) >=2b) and symptomatic intracerebral haemorrhagic (sICH) transformation.

209 further in clinical settings, especially for haemorrhagic states.

210 ; p<0.0001), mainly driven by a reduction in haemorrhagic stroke (0.49, 0.38-0.64; p<0.0001).

211 and there were significant reductions in non-haemorrhagic stroke (131 [2.8%] vs 174 [3.8%]; RR 0.75,

212 number of people with incident ischaemic and haemorrhagic stroke (37% and 47% increase, respectively)

213 rterial ischaemic stroke (AIS) and 43 with a haemorrhagic stroke (HS) were identified.

214 stroke (RR 68%, 95% CI 1.52-1.87, P < .001), haemorrhagic stroke (RR 114%, 95% CI 1.74-2.64, P < .001

215 significant (0.20%vs 0.21% per year, p=0.4: haemorrhagic stroke 0.04%vs 0.03%, p=0.05; other stroke

216 tated regimens than in primary intervention (haemorrhagic stroke 15 [0.7%] vs two [0.1%], p=0.0014; t

217 mg), and one death (<1%; upadacitinib 15 mg, haemorrhagic stroke [ruptured aneurysm]) were reported i

218 Haemorrhagic stroke accounts for approximately 20% of st

219 icant increase of 22% (5-30) in incidence of haemorrhagic stroke and a 6% (-7 to 18) non-significant

220 e (cSVD) is a leading cause of ischaemic and haemorrhagic stroke and a major contributor to dementia.

221 Haemorrhagic stroke and total stroke rates were higher i

222 amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment.

223 <0.0001), with a non-significant increase in haemorrhagic stroke but reductions of about a fifth in t

224 regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010.

225 of grip strength at 4 weeks post-stroke and haemorrhagic stroke explained the underestimated classif

226 mortality data suggest that the incidence of haemorrhagic stroke has fallen in the past 20 years, but

227 andardised mortality rates for ischaemic and haemorrhagic stroke have decreased in the past two decad

228 For haemorrhagic stroke in low-income and middle-income coun

229 country-specific estimates for ischaemic and haemorrhagic stroke incidence, mortality, mortality-to-i

230 Worldwide, the burden of ischaemic and haemorrhagic stroke increased significantly between 1990

231 clinical endpoints (all cause mortality, non-haemorrhagic stroke or systemic embolism, and major blee

232 The burden of ischaemic and haemorrhagic stroke varies between regions and over time

233 e.g. new-onset diabetes mellitus or possibly haemorrhagic stroke) and long-term data are needed to ad

234 eg, neuroprotective drugs and treatments for haemorrhagic stroke) options in the prehospital setting,

235 ity, myocardial infarction, and ischaemic or haemorrhagic stroke), hospital events for heart failure

236 na) or stroke (including ischaemic stroke or haemorrhagic stroke).

237 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial infarction, deep v

238 d systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial inf

239 e, 0.58 million deaths (0.57 to 0.60) due to haemorrhagic stroke, and 0.34 million deaths (0.32 to 0.

240 diposity, including ischaemic heart disease, haemorrhagic stroke, and ischaemic stroke.

241 management, reversal of warfarin effects in haemorrhagic stroke, and management of cerebral emergenc

242 g ischaemic heart disease, ischaemic stroke, haemorrhagic stroke, and other cardiovascular diseases)

243 orta, atrial fibrillation, ischaemic stroke, haemorrhagic stroke, and venous thromboembolism.

244 tients had CNS events (six ischaemic and one haemorrhagic stroke, eight transient ischaemic attacks,

245 For haemorrhagic stroke, incidence reduced significantly by

246 lure, atrial fibrillation, all-cause stroke, haemorrhagic stroke, ischaemic stroke, hypertension, aor

247 Except for haemorrhagic stroke, lower early adulthood BMI (<20.5 kg

248 myocardial infarction or coronary death, non-haemorrhagic stroke, or any arterial revascularisation p

249 hough migraine appears to be associated with haemorrhagic stroke, the migraine aura status has a smal

250 orta, atrial fibrillation, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, cardiovascu

251 troke events, including ischaemic stroke and haemorrhagic stroke, were identified through hospital an

252 c options for collagen IV diseases including haemorrhagic stroke.

253 wo persons had severe amyloid angiopathy and haemorrhagic stroke.

254 amyloid angiopathy is an important cause of haemorrhagic stroke.

255 cant protective effect on both ischaemic and haemorrhagic stroke.

256 speptins are upregulated in rodent models of haemorrhagic stroke.

257 ne of the biomarkers correlated with risk of haemorrhagic stroke.

258 new-onset diabetes mellitus, and, probably, haemorrhagic stroke.

259 ) for ischaemic stroke; 1.56 (1.19-2.05) for haemorrhagic stroke; 1.84 (1.59-2.13) for unclassified s

260 nts aged 18-83 years with ischaemic (ie, non-haemorrhagic) stroke with a baseline National Institutes

261 e were no apparent differences in numbers of haemorrhagic strokes (24 [0.4%] vs 25 [0.4%]) or deaths

262 n encountered in patients with ischaemic and haemorrhagic strokes, subarachnoid haemorrhage, cerebrov

263 ortion of ischaemic strokes and a decline in haemorrhagic strokes.

264 sis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes.

265 Fatty Liver Haemorrhagic Syndrome (FLHS) is mostly observed in layin

266 Hereditary haemorrhagic telangiectasia (HHT) [corrected] is a vascu

267 Hereditary haemorrhagic telangiectasia (HHT) is a vascular dysplasi

268 enesis and has been implicated in hereditary haemorrhagic telangiectasia (HHT), atherosclerosis, tumo

269 es on a human vascular dysplasia, hereditary haemorrhagic telangiectasia (HHT), wherein arterial and

270 Juvenile polyposis and hereditary haemorrhagic telangiectasia are autosomal dominant disor

271 ng of both juvenile polyposis and hereditary haemorrhagic telangiectasia phenotypes.

272 gene with the inherited disorder Hereditary Haemorrhagic Telangiectasia Type 1 (HHT1), a disease cha

273 mutations in the ALK1 gene cause hereditary haemorrhagic telangiectasia type 2 (HHT2), a disabling d

274 vascular lesions associated with hereditary haemorrhagic telangiectasia, especially occult arteriove

275 Hereditary haemorrhagic telangiectasia, or Osler-Rendu-Weber (ORW)

276 ardiovascular disorders including hereditary haemorrhagic telangiectasia, pulmonary arterial hyperten

277 lmonary arterial hypertension and hereditary haemorrhagic telangiectasia.

278 n in smooth muscle that occurs in hereditary haemorrhagic telangiectasia.

279 In a mouse model of CAA there is a low haemorrhagic threshold after thrombolytic therapy compar

280 the pre-hospital setting by the US Army, on haemorrhagic tolerance in humans is unknown.

281 the hypothesis that ketamine does not impair haemorrhagic tolerance in humans.

282 mia (HR 2.91, 95% CI 1.08 to 7.84) and early haemorrhagic transformation (HR 5.35, 95% CI 2.22 to 12.

283 Thrombolysis-related haemorrhagic transformation (HT) subtypes may have diffe

284 Complications of rt-PA therapy, such as haemorrhagic transformation and angio-oedema, are review

285 administration of tPA (10 mg/kg) resulted in haemorrhagic transformation in the ischaemic territory 1

286 Haemorrhagic transformation is a complication of recombi

287 harmful intracranial haemorrhage, including haemorrhagic transformation of the infarct.

288 ilable to rescue ischaemic brain tissue; the haemorrhagic transformation that can cause severe functi

289 ter delayed tPA treatment in ischaemic mice, haemorrhagic transformation was significantly decreased,

290 l venous thrombosis, head trauma, or tumour; haemorrhagic transformation within an infarct; and refer

291 gical complications, such as brain oedema or haemorrhagic transformation, occur earlier than do medic

292 t-emergent adverse event was non-symptomatic haemorrhagic transformation, which occurred in 17 (31%)

293 travenous thrombolysis due to concerns about haemorrhagic transformation.

294 wn after ischaemic stroke and lead to lethal haemorrhagic transformation.

295 gulatory T cell transfer against tPA-induced haemorrhagic transformation.

296 e increased cerebrovascular permeability and haemorrhagic transformation.

297 alignant brain tumours, ischaemic stroke and haemorrhagic traumatic contusion.

298 e clearest association was with the familial haemorrhagic variant where all four families tested had

299 oke was subdivided into fatal, ischaemic and haemorrhagic, with higher magnitude associations for fat

300 mary outcome was total stroke (ischaemic and haemorrhagic) within 90 days.